Concepedia

Chinyu Su

CS

Statistics

Publications

55

Citations

6.5K

H-Index

32

Active since

1999

Affiliations

Pfizer (United States)(Current)

Icahn School of Medicine at Mount Sinai

Hospital Clínic de Barcelona

University of California San Diego

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas

Chinyu Su is an author at Pfizer (United States) specializing in inflammatory bowel disease, ulcerative colitis pharmacotherapy, and pharmacotherapy.

Publications per year

1999–2025

55

Publications

55

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

William J. Sandborn, Chinyu Su, Bruce E. Sands et al. · New England Journal of Medicine · 2017 · 1.7K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

William J. Sandborn, Subrata Ghosh, Julián Panés et al. · New England Journal of Medicine · 2012 · 799 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response

Chinyu Su, Xiaoming Wen, Shannon T. Bailey et al. · Journal of Clinical Investigation · 1999 · 758 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +17

Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials

William J. Sandborn, Julián Panés, Geert D’Haens et al. · Clinical Gastroenterology and Hepatology · 2018 · 244 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib

Kevin Winthrop, Gil Melmed, Séverine Vermeire et al. · Inflammatory Bowel Diseases · 2018 · 209 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +16

1–5 of 55